Edwards Lifesciences Corporation EW
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.63% | 16.70% | 13.26% | 14.67% | 11.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.63% | 16.70% | 13.26% | 14.67% | 11.89% |
| Cost of Revenue | 13.94% | 20.23% | 17.39% | 31.30% | 25.01% |
| Gross Profit | 13.54% | 15.74% | 12.16% | 10.66% | 8.58% |
| SG&A Expenses | 11.79% | 12.13% | 22.37% | 22.12% | 12.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 48.36% | 25.65% | 37.00% | -155.80% | -- |
| Total Operating Expenses | 10.91% | 13.07% | 16.06% | 17.49% | 10.71% |
| Operating Income | 20.56% | 25.57% | 5.11% | 7.81% | 15.03% |
| Income Before Tax | 29.89% | 5.78% | -76.83% | -13.51% | 4.22% |
| Income Tax Expenses | 332.97% | 11.38% | -41.91% | 37.84% | 221.50% |
| Earnings from Continuing Operations | -28.13% | 4.70% | -81.39% | -19.28% | -7.72% |
| Earnings from Discontinued Operations | -- | -- | -31.30% | -100.07% | -540.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -70.59% | -- | -100.00% | -42.86% | 30.77% |
| Net Income | -27.40% | 6.34% | -76.35% | -90.52% | -9.04% |
| EBIT | 20.56% | 25.57% | 5.11% | 7.81% | 15.03% |
| EBITDA | 19.87% | 24.43% | 4.56% | 11.42% | 13.23% |
| EPS Basic | -26.06% | 7.75% | -75.97% | -90.32% | -6.71% |
| Normalized Basic EPS | 15.67% | 40.73% | 25.49% | 1.64% | 16.99% |
| EPS Diluted | -25.39% | 8.14% | -76.58% | -90.34% | -7.54% |
| Normalized Diluted EPS | 15.59% | 40.58% | 25.35% | 1.62% | 17.25% |
| Average Basic Shares Outstanding | -1.81% | -1.31% | -1.59% | -2.09% | -2.51% |
| Average Diluted Shares Outstanding | -1.75% | -1.21% | -1.47% | -2.07% | -2.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |